News Column

Statement of the National Alliance for Hispanic Health on the Food and Drug Administration (FDA) Advisory Committee Plan

PR Newswire

WASHINGTON, July 24 /PRNewswire/ -- "In our 21st century health system, the need for transparency is greater than ever. The advisory committee plan announced today strengthens FDA's commitment to transparency and its mission of protecting the health and well-being of the public," said Dr. Jane L. Delgado, President and CEO of the National Alliance for Hispanic Health (the Alliance).

The FDA announced steps to be taken over the next few months that will include:

* Issuing a guidance identifying more clearly the conditions under which conflict of interest waivers are granted. * Issuing a guidance specifying when waivers of conflict of interest will be disclosed to the public and what information will be made available. * Issuing a guidance specifying when briefing materials used at advisory committee meetings will be made publicly available. * Providing greater public dissemination of advisory committee schedules through increased mailings to public groups, and providing electronic notifications through an FDA advisory committee list serve and posting on the FDA web site. * Implementation of a more streamlined approach to the appointment of members to the agency's drug-related advisory committees.

"The FDA's open process has made it the gold standard for consumer health protection throughout the world," added Dr. Delgado in announcing the Alliance's support for the FDA plan announced today.

"Today's announcement will help to ensure that the FDA continues to be the premier consumer health protection agency," Dr. Delgado concluded. National Alliance for Hispanic Health

Web site:

Source: PR Newswire

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters